FindTrial
Sign In

Real world study on the efficacy of olaparib in patients with metastatic castration resistant prostate cancer harboring genomic variants in homologous recombination repair genes

Real world study on the efficacy of olaparib in patients with metastatic castration resistant prostate cancer harboring genomic variants in homologous recombination repair genes

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051359
Enrollment
Unknown
Registered
2021-09-21
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Treatment group:Olaparib

Sponsors

Renji Hospital, Shanghai Jiaotong University, School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.According to EAU-EASTRO-SIOG 2016 guidelines, metastatic castration resistant prostate cancer was clinically diagnosed; 2.Homologous recombination repair gene variant was confirmed by gene detection (germline and / or somatic); 3.Olaparib was previously used to treat metastatic castration resistant prostate cancer.

Exclusion criteria

Exclusion criteria: 1.The patient was diagnosed as neuroendocrine / small cell prostate cancer by histopathology; 2.Previously diagnosed with any other malignancy.

Design outcomes

Primary

MeasureTime frame
Prostate specific antigen response rate;—

Secondary

MeasureTime frame
Prostate specific antigen progression-free survival;Overall survival;—

Countries

China

Contacts

Public ContactXue Wei

Renji Hospital, Shanghai Jiaotong University, School of Medicine

xuewei@renji.com+86 13801931604

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026